Zusammenfassung
In diesem Kapitel werden die Suchtmittel mit ihren Substanzcharakteristika, Entzugssyndromen, Entwöhnungsmaßnahmen und ihrer Intoxikationssymptomatik bzw. -therapie im Hinblick auf die verschiedenen spezifischen klinischen Syndrome der Suchtkrankheiten behandelt (► 7.1.2, Tab. 7.1). Die Gliederung erfolgt nicht nach Medikamentengruppen, sondern nach Suchtmitteln.
Preview
Unable to display preview. Download preview PDF.
Literatur
Anthenelli RM, Morris C, Ramey TS et al (2013) Effects of varenicline on smoking cessation in adults with stably treated current or past major depression: a randomized trial. Ann Intern Med 159(6):390–400
Beck A, Heinz A (2013) Alcohol-related aggression - social and neurobiological factors. Dtsch Arztebl Int 110(42):711–715
Brown RM, Kupchik YM, Kalivas PW (2013) The story of glutamate in drug addiction and of N-acetylcysteine as a potential pharmacotherapy- JAMA Psychiatry 70(9): 895
Butelman ER, Yuferov V, Kreek MJ (2012) κ-Opioid receptor/dynorphin system: genetic and pharmacotherapeutic implications for addiction. Trends Neurosci 35(10):587–796
Foa EB, Yusko DA, McLean CP et al (2013) Concurrent naltrexone and prolonged exposure therapy for patients with comorbid alcohol dependence and PTSD: A randomized clinical trial. JAMA 310:488
Grant JE, Odlaug BL, Chamberlain SR et al (2014) A randomized, placebo-controlled trial of N-acetylcysteine plus imaginal desensitization for nicotine-dependent pathological gamblers. J Clin Psychiatry 75(1):39–45
Grosshans M, Lemenager T, Vollmert C et al (2013) Pregabalin abuse among opiate addicted patients. Eur J Clin Pharmacol 69(12):2021–2025
Heinzerling KG1, Swanson AN, Hall TM et al (2014) Randomized, placebo-controlled trial of bupropion in methamphetamine-dependent participants with less than daily methamphetamine use. Addiction. doi: 10.1111/add.12636 (Epub ahead of print)
Hohmann N, Mikus G, Czock D (2014) Wirkungen und Risiken neuartiger psychoaktiver Substanzen. Dt Ärztebl 9:139–147
Kampman KM, Pettinati HM, Lynch KG et al (2013) A double-blind, placebo-controlled trial of topiramate for the treatment of comorbid cocaine and alcohol dependence. Drug Alcohol Depend 133(1):94–99
Kishi T, Sevy S, Chekuri R, Correll CU (2013) Antipsychotics for primary alcohol dependence: a systematic review and meta-analysis of placebo-controlled trials. Clin Psychiatry 74(7):e642–e654
Lange-Asschenfeldt C, Muller MJ, Szegedi A et al (2003) Symptom-triggered versus standard chlormethiazole treatment of inpatient alcohol withdrawal: clinical implications from a chart analysis. Eur Addict Res 9:1–7
Levin FR, Mariani J, Brooks DJ et al (2013) A randomized double-blind, placebo controlled trial of venlafaxine-extended release for co-occurring cannabis dependence and depressive disorders. Addiction 108(6):1084–1094
Mann K, Fauth-Bühler M, Seiferth N, Heinz A; Expertengruppe Verhaltenssüchte der DGPPN (2013) Konzept der Verhaltenssüchte und Grenzen des Suchtbegriffs. Nerven arzt 84(5): 548–556
Meier MH, Caspi A, Ambler A et al (2012) Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc Natl Acad Sci USA 109(40):E2657–E2664
Nowak D, Jörres RA, Rüther T (2014) E-cigarettes-prevention, pulmonary health, and addiction. Dtsch Arztebl Int 111(20):349–355
Sigmon SC, Dunn KE, Saulsgiver K et al (2013) A randomized, double-blind evaluation of buprenorphine taper duration in primary prescription opioid abusers. JAMA Psychiatry 70(12):1347–1354
Soyka M (2014) Nalmefene for the treatment of alcohol dependence: a current update. Int J Neuropsychopharmacol 17(4):675–684
Stapleton J, West R, Hajek P et al (2013) Randomized trial of nicotine replacement therapy (NRT), bupropion and NRT plus bupropion for smoking cessation: effectiveness in clinical practice. Addiction 108(12):2193–2201
Tiihonen J, Krupitsky E, Verbitskaya E et al (2012) Naltrexone implant for the treatment of polydrug dependence: a randomized controlled trial. Am J Psychiatry 169(5):531–536
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Benkert, O. (2015). Medikamente zur Behandlung von Abhängigkeit und Entzugssyndromen. In: Kompendium der Psychiatrischen Pharmakotherapie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-54769-0_7
Download citation
DOI: https://doi.org/10.1007/978-3-642-54769-0_7
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-54768-3
Online ISBN: 978-3-642-54769-0
eBook Packages: Medicine (German Language)